LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Field Test for Zika Virus Combines PCR Components into a Single Low Cost Unit

By LabMedica International staff writers
Posted on 18 Jul 2016
Image: The prototype of a rapid, low-cost genetic test for the Zika virus. The patient provides a saliva sample, and the appearance of a blue color in the device\'s lid indicates the presence of the virus (Photo courtesy of the University of Pennsylvania).
Image: The prototype of a rapid, low-cost genetic test for the Zika virus. The patient provides a saliva sample, and the appearance of a blue color in the device\'s lid indicates the presence of the virus (Photo courtesy of the University of Pennsylvania).
A prototype PCR-based field test for the detection of the Zika virus (ZIKV) incorporates all required components and delivers accurate results in only about 40 minutes.

Rapid and reliable diagnostics for ZIKV are vital because ZIKV-infected individuals display no symptoms or nonspecific symptoms similar to other viral infections. Since immunoassays lack adequate sensitivity and selectivity and are unable to identify active state of infection, molecular diagnostics are an effective means to detect ZIKV soon after infection and throughout pregnancy.

Investigators at the University of Pennsylvania (Philadelphia, USA) recently described a highly sensitive reverse-transcription loop-mediated, isothermal amplification (RT-LAMP) assay for rapid detection of ZIKV. The benefit of using the RT-LAMP procedure was that while it required that the sample be kept at a specific temperature, it did not demand that it be cycled through multiple precise temperature changes as in RT-PCR. On the other hand, RT-LAMP required more highly specialized DNA primers than did RT-PCR.

To deal with the primer problem, the investigators identified highly conserved regions of the Zika virus genome that were divergent from other known pathogens. They then designed appropriate primers to recognize this sequence. The investigators then engineered a low-cost, point-of-care system that consisted of a diagnostic cassette and a processor. The cassette isolated, concentrated, and purified nucleic acids from a patient's saliva sample and then carried out enzymatic amplification. The test results were indicated by the change in the color of a dye, which was inspected visually. For thermal control of the cassette, they used a chemically heated cup – adapted from military ration kits – without need for electrical power.

The investigators demonstrated the utility of this novel POC diagnostic system by detecting ZIKV in oral samples with sensitivity of five plaque-forming units (PFU) in less than 40 minutes. This low cost technology (estimated to be about two USD per test device) is particularly suitable for resource-poor settings, where centralized laboratory facilities, funds, and trained personnel are in short supply, and for use in doctors’ offices, clinics, and at home.

"Our work represents a proof of concept at this stage," said contributing author Dr. Haim Bau, professor of mechanical engineering and applied mechanics at the University of Pennsylvania. "Before the assay can be adapted for medical use, we must experiment with patients' samples and make assure that our assay and system match the performance of the gold standard and operate reproducibly and reliably. We are fortunate to have dedicated colleagues in endemic regions ready to assist us in this task."

The ZIKV field test was described in detail in the June 16, 2016, online edition of the journal Analytical Chemistry.

Related Links:
University of Pennsylvania

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more